These days, the topic of GLP-1 drugs will come up in any discussion about weight loss. The terms “semaglutide,” “tirzepatide,” “Ozempic,” and “Wegovy” have entered common usage in a way that seems genuinely novel. The price hasn’t changed—at least not quickly enough. Without insurance, brand-name Wegovy still costs between $1,300 and $1,500 per month. For the majority of working people, that number puts an end to the conversation before it even begins.
Platforms like MEDVi have established themselves there. The business, which provides direct-to-consumer telehealth services, has centered its entire pitch on the notion that GLP-1 drugs don’t have to be as expensive as a month’s rent. MEDVi is positioning itself in a market where the math truly makes sense for average patients, starting at $179 for the first month of compounded semaglutide injections. It’s difficult to ignore how drastically that number contrasts with what the big pharmaceutical companies are charging.
However, the first-month price merits further consideration. Following that trial period, the monthly cost of compounded semaglutide injections is $299, while the oral tablet version is $349. The point is that it’s still a small portion of brand-name prices, but patients who only notice the $179 headline and don’t read any further might be a little taken aback when the second invoice shows up. To be fair, the refill pricing is clearly stated, and MEDVi has been transparent about this in its published materials. Nevertheless, it is important to comprehend the difference between initial and continuing costs before committing.
In addition to the cost of the medication itself, MEDVi charges a $99 monthly membership fee for patients interested in brand-name drugs, such as Wegovy or Zepbound by injection or the more recent Wegovy pill. In telehealth, that model is rather prevalent. The physician review, care coordination, and administrative layer that keeps everything running smoothly are all covered by the membership. The degree to which a patient truly desires hand-holding will likely determine whether it feels like overhead or value. While some people would prefer to just get their medication and move on, others find that structure comforting.
The baseline features of MEDVi are truly competitive. The standard offering includes a physician review, a customized plan, one-on-one guidance, and free shipping. The package also includes care coaching and dietitian visits, which is noteworthy because many rival platforms only offer these services at higher price points or charge separately for them. The HSA and FSA approval of MEDVi is also important because it reduces the effective out-of-pocket expense for patients with those accounts, sometimes significantly.
This is part of a larger narrative that extends beyond MEDVi in particular. The demand for these drugs continuously exceeds what insurance will cover and what brand-name pricing permits, which has caused the compounded GLP-1 market to grow quickly. Although compounded semaglutide is not the same as FDA-approved Wegovy, it is prescribed by licensed physicians and has the same active ingredient, placing it in a regulatory gray area. Because it works within that framework, MEDVi can set aggressive prices. It is genuinely unclear whether compounded alternatives will continue to be available as the regulatory environment changes, and prospective patients should consider this when making long-term decisions.
According to reports, the signup process is quick; many patients receive their first shipment in about a week, which is quick by any measure. That speed carries a lot of emotional weight for someone who has already spent months investigating options and encountering insurance dead ends. Patients describe receiving medication without a three-month wait and being finally taken seriously by a medical platform as a relief rather than merely a convenience.
The cost of MEDVi weight loss ultimately boils down to a fairly straightforward formula. $299 per month seems like a substantial alternative to the $1,300+ monthly reality of name-brand GLP-1 drugs, and it most likely is. The affordability of MEDVi in comparison to Wegovy isn’t really the question. The question is whether $299 a month is affordable for the course of treatment, which for the majority of patients entails months rather than weeks. GLP-1 drugs typically function when taken consistently. In the end, who benefits is determined by the cost of remaining on them, compounded over time.
